Request Board approval authorizing the Sheriff of Los Angeles County (County) to accept and execute a grant award in the amount of $420,000 from the State of California (State), Office of Traffic Safety (OTS), for the Fiscal Year (FY) 2017 Regional Drug-Impaired Driving Forensic Toxicology Program (Program), Grant Agreement Number DI1721 (Agreement) for the grant period from January 1, 2017, through September 30, 2018. The Program is funded through the National Highway Traffic Safety Administration (NHTSA) grant funds, CFDA Number 20.616, passing through the State. The grant will fund the County’s Scientific Services Bureau (SSB), Forensic Toxicology Unit, which will continue targeting traffic safety enforcement.

SUBJECT

April 11, 2017

The Honorable Board of SupervisorsCounty of Los Angeles383 Kenneth Hahn Hall of Administration Los Angeles, California 90012 Dear Supervisors:

ACCEPT A GRANT AWARD FROM THE STATE OF CALIFORNIAOFFICE OF TRAFFIC SAFETY FOR THE REGIONAL DRUG-IMPAIRED

DRIVING FORENSIC TOXICOLOGY PROGRAM(ALL DISTRICTS) (3 VOTES)

IT IS RECOMMENDED THAT THE BOARD:

1. Adopt the attached Resolution (Attachment I) authorizing the Sheriff, or his designee, as an agent for the County, to accept and execute Agreement Number DI1721 (Attachment II) with OTS using the NHTSA grant funds, CFDA Number 20.616, in the amount of $420,000 with no matching funds for the grant period from January 1, 2017, through September 30, 2018, and all future amendments, modifications, augmentations, and reimbursement requests necessary to effectuate the Program.

2. Authorize the Internal Services Department (ISD), as the County’s Purchasing Agent, to proceed with the acquisition of a liquid chromatography tandem mass spectrometry (LCTMS) for the confirmatory and quantitative analysis of drug-impaired driving submissions, not to exceed $400,000.

3. Delegate authority to the Sheriff, as an agent for the County, to apply and submit a grant application to OTS for the Program, when and if such future funding becomes available.

PURPOSE/JUSTIFICATION OF RECOMMENDED ACTION

The purpose and goal of the Program is to purchase a LCTMS for the confirmatory and quantitative analysis of drug-impaired driving submissions, and to authorize the Purchasing Agent to proceed with the solicitation and acquisition of this capital asset with a cost exceeding $250,000. This equipment will aid local law enforcement and prosecutorial agencies in the investigation and prosecution of drug-impaired driving cases, thereby increasing safety on roadways within the County. In addition, the Department’s SSB will partner with the County’s District Attorney’s (DA) Office in efforts to better equip Deputy District Attorneys (DDA’s) to prosecute drug-impaired driving cases.

Implementation of Strategic Plan GoalsThe Program meets the County’s Strategic Plan, Goal 3, Integrated Services Delivery, by providing equipment for a comprehensive traffic safety program to the 42 contracted cities and target areas identified with greater traffic issues within the County.

FISCAL IMPACT/FINANCING

This will be the first year of funding for this Program. Funding of $420,000 was included in the Department’s FY 2016-17 Supplemental Budget request.

The $420,000 in grant funding will be used to fund a capital asset purchase, to include the LCTMS, equipment, ($400,000), and travel and training expenses ($20,000).

FACTS AND PROVISIONS/LEGAL REQUIREMENTS

The grant period will commence on January 1, 2017, and end on September 30, 2018. This grant award will enable the Department’s SSB to continue to target traffic safety enforcement operations within various contract cities throughout the County during the duration of the grant.

On October 16, 2001, the Board adopted a policy whereby departments will obtain Board approval to purchase or finance equipment with a unit cost of $250,000 or greater prior to submitting their requisition to the County’s Purchasing Agent.

The County agrees to indemnify, defend, and save harmless the State, its officers, agents, and employees from any and all claims and losses accruing or resulting to any and all contractors, subcontractors, suppliers, laborers, and any other person, firm, or corporation furnishing or supplying work services, materials, or supplies in connection with the performance of the Agreement, and from any and all claims and losses accruing or resulting to any person, firm, or corporation who may be injured or damaged by the County in the performance of the Agreement.

This Board letter has been reviewed and the Resolution has been approved as to form by County Counsel.

The Honorable Board of Supervisors4/11/2017Page 2

CONTRACTING PROCESS

The procurement of this equipment is a commodity purchase under the statutory authority of the Purchasing Agent. The purchase will be requisitioned through and accomplished by the Purchasing Agent in accordance with the County’s purchasing policies and procedures established by ISD.

IMPACT ON CURRENT SERVICES (OR PROJECTS)

This Board letter was forwarded to the DA Office, the Public Defender’s Office, and the Alternate Public Defender’s Office for review. Upon review of the Board letter, the DA Office and the Public Defender’s Office have both confirmed the Program will have minimal impact on their services, while the Alternate Public Defender’s Office believes that continued acceptance of this grant funding will impact their department by increasing arrests and criminal complaint filings, which can be managed with existing department resources.

CONCLUSION

Upon Board approval, please return a copy of the adopted Board letter and two original signed Resolutions to the Department’s Grants Unit.

JIM McDONNELL

Sheriff

Enclosures

Sincerely,

JM:II:ii

The Honorable Board of Supervisors4/11/2017Page 3

Los Angeles County Chief Executive Office Grant Management Statement for Grants Exceeding $100,000

Department: LOS ANGELES COUNTY SHERIFF'S DEPARTMENT

Grant Project Title and Description: Regional Drug-Impaired Driving Forensic Toxicology Program

The main purpose and goals of the Program is to purchase a liquid chromatography tandem mass spectrometry (LC/MS/MS) for the confirmatory and quantitative analysis of drug-impaired driving submissions, and to authorize the Purchasing Agent to proceed with the sol ic itation and acqu isition of this capital asset with a cost of more than $250,000. This equipment will aid local law enforcement and prosecutorial agencies in the investigation and prosecution of drug-impaired driving cases, thereby increasing safety on roadways within LA County. In addition, the Department's SSB will partner with the County's District Attorney's Office (LADA) in LADA's efforts to better equip Deputy District Attorneys (DDA's) to prosecute drug-impaired driving cases.

Funding Agency State of California - Office of Traffic Safety (OTS)

Program (Fed. Grant# /State Bill or Code#)

Grant # 011721

Grant Acceptance Deadline

Upon Board Approval

Total Amount of Grant Funding: $420,000 County Match: $0 Grant Period: l2 Months Begin Date: January 1, 2017 End Date: September 30, 2018 Number of Personnel Hired Under This Grant: 0 Full Time: N/ A Part Time: N/ A

Obligations lmQosed on the County When the Grant ExQires Will all personnel hired fo r this program be informed this is a grant-funded program? Yes - No _x_

Will all personnel hired for this program be placed on temporary ("N") items? Yes - No __x_

Is the County obligated to continue this program after the grant expires? Yes - No _x_

If the County is not ob i igated to continue this program after the grant expires, the Department will:

a). Absorb the program cost without reducing other services Yes_ No X

b) . Identify other revenue sources Yes_ No X (Describe) _____________________________ _

c) . Eliminate or reduce, as appropriate, .positions/program costs funded by the grant. Yes _ No _x_

Impact of additional personnel on existing space: None

Other requirements not mentioned above: None

I

Department Head Signature _________________ _ Date ______ _

RESOLUTION

WHEREAS the County of Los Angeles desires to undertake a certain

project designated as the Los Angeles County Sheriff's Department's Fiscal Year

2017 Regional Drug-Impaired Driving Forensic Toxicology Program, to be

financed with grant funds from the National Highway Traffic Safety Administration

(NHTSA), CFDA Number 20.616, passing through the State of California, Office

of Traffic Safety (OTS).

NOW, THEREFORE BE IT RESOLVED that the Sheriff of the County of

Los Angeles or his designee is hereby authorized to accept and execute, on

behalf of Los Angeles County Board of Supervisors, Grant Agreement Number

Dl1721 in the amount of $420,000 from the OTS, and to execute and submit all

other necessary grant documents, including any extensions, modifications,

agreements, contracts and augmentations with the State in relation thereto.

BE IT FURTHER RESOLVED that the Sheriff of the County of Los

Angeles agrees to the funding terms and conditions of OTS, including any

amendment thereof.

IT IS AGREED that, as required by Grant Award Agreement Number

Dl1721 , the County of Los Angeles shall indemnify, defend, and save harmless

the State of California, its officers, agents, and employees from any and all

claims and losses accruing or resulting to any and all contractors,

subcontractors, suppliers, laborers, and any other person, firm, or corporation

1

State of California- Office of Traffic Safety GRANT AGREEMENT - Page 1 OTS-38 (Rev. 4/ 16)

GRANT NUMBER

DII 72 1

1. GRANT TITLE

REGIONAL DRUG-IMPAIRED DRIVING FORENSIC T OXICOLOGY PROGRAM

2. NAME OF AGENCY

LOS A NGELES C OUNTY SHERIFF'S D EPARTM ENT 3. AGE CY UNIT TO ADMINISTER GRANT

SCIENTIFIC SERVICES B UREAU (CRIME LABORATORY)

5. GRANT DESCRIPTION

4. GRANT PERIOD

From: 1/1/17 To: 9/30/18

The Los Angeles County Sheriff's Department (LASD) - Scientific Services Bureau (SSB) is responsible for all ante-mortem criminal forensic toxicology analyses within the County of Los Angeles, exclusive only of Los Angeles City. This includes service to over I 00 local, state, and federal law enforcement agencies, including the California Highway Patrol. LASD-SSB will introduce the use of liquid chromatography tandem mass spectrometry (LC/MS/MS) for the confirmatory and quantitative analysis of drug-impaired driving submissions. This equipment will aid local law enforcement and prosecutorial agencies in the investigation and prosecution of drug-impaired driving cases, thereby increasing safety on roadways within Los Angeles County. In addition, LASD-SSB will partner with the Los Angeles County District Attorney's Office (LADA) in LADA 's efforts to better equip Deputy District Attorneys (DDAs) to prosecute drug-impaired driving cases.

6. FEDERAL fUNDS ALLOCATED UNDER TillS AGREEMENT SHALL NOT EXCEED: $ 420,000.00

7. TERMS AND CONDITIONS: The parties agree to comply with the terms and conditions of the following which are by this reference made a part of the Agreement:

• Schedule A (OTS-38b) - Problem Statement, Goals and • Exhibit A -Certifications and Assurances Objectives and Method of Procedure • Exhibit B* - OTS Grant Program Manual

• Schedule B (OTS-38d)- Detailed Budget Estimate and Sub-Budget Estimate (if applicable)

• Schedule B-1 (OTS-38f) - Budget Narrative and Sub­Budget Narrative (if applicable)

*Items shown with an asterisk(*), are hereby incorporated by reference and made a part of this agreement as if attached hereto.

These documents can be viewed at the OTS home web page under Grants: www.ots.ca.gov.

We, the officials named below, hereby swear under penalty of perjury under the laws of the State of California that we are duly authorized to legally bind the Grant recipient to the above described Grant terms and conditions.

£N WITNESS WHEREOF. this Agreement has been executed by the parties hereto. 8. APPROVALSIGNAT RES A. GRANT DIRECTOR

NAME: J ames Carroll

Tm..E: C rime Laboratory Assistant Director

PHONE: 562-334-4308

FAX 562-940-0337

ADDRESS. 77 17 G oloodr inas St. Downey, C A 90242

&~~ ,. (Signature)

C. F ISCAL OR ACCOUNTING O FFICIAL

NAME: Rick Cava ta io

Tm..E: Director

ADDRESs: 2 11 W. Temple St ., 6'b Floor Los Angeles, CA 90012

E-MAIL: ,?.7vata,..®~sd.or

• ~\()4 4.JJf:) ~ ' (Signarure)

OVb.,/(7 (Date)

PHONE: 213-229-329 1

FAX: 323-415- l 083

(Date)

B. AUTHORIZING O FFICIAL OF AGENCY

NAME: J im McDonnell PHONE: 213-229-3000 Tm..E· Sher iff

FAX:

ADDRESS 2 11 W. T emple S t. Los Angeles, C A 90012

E-MAIL ' grants unit@ lasd.org

(Signature)

D. O FFICE AUTHORIZED T O R ECEIVE P AYMENTS

NA>\>IE: Sheriff's Department, Grants

ADDRESS 211 w_ T emple St_, 6'b Floor

Los A ngeles, C A 90012

9. DUNS NUMBER

DUNS #: 02-895-0678 REGISTERED 211 W. Temple St. ADORES~~~ Los Angeles, CA 90012-3205

(Date)

10. Fin Action No. Date: 12. TYPE OF AGREEMENT Initial X Revision Cont.

Revision No. Date:

11. Action Taken

Obligated This Action

Previously Obligated

Total Amount Obligated

TOTAL FUNDS PROGRAMMED

14. FUNDING DETAIL - FISCAL YEAR GRANT PERIOD ENDING:

NAME: NAME:

TITLE: TITLE:

PHONE:

E-MAIL:

Office of Traffic Safety Office of Traffic Safety

2208 Kausen Drive, Suite 300 2208 Kausen Drive, Suite 300

Elk Grove, CA 95758 Elk Grove, CA 95758

Signature Signature

julie.schilling@ots.ca.gov

JULIE SCHILLING

Director

13. FUNDING DISPOSITION & STATUS

A. APPROVAL RECOMMENDED BY B. AGREEMENT & FUNDING AUTHORIZED BY

15. GRANT APPROVAL & AUTHORIZATION TO EXPEND OBLIGATED FUNDS

Program Coordinator

Total

2013-14

RHONDA L. CRAFT

Initial approval of 2017 HSP funds obligated.

420,000.00

420,000.00

0.00

EFFECTIVE DATE OF AGREEMENT: 10/1/2016 GRANTEELOS ANGELES COUNTY SHERIFF

DEPARTMENT

1 2/2/2017

GRANT NO.

(916) 509-3018

2017

420,000.00

Fiscal Year

2014-15

420,000.00

420,000.00$ TOTAL FEDERAL FUNDS:

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0521-0890-101 (10/15)

0521-0890-101 (23/16)

-

-

-

10/15

23/16

- -

-

-

2015

2016

-

-

20.616

-

-

-

-

405d AL

405d AL

-

-

-

Page 2 (Office of Traffic Safety Use Only)

FUND CFDA ITEM/APPROPRIATION F.Y. CHAPTER

9/30/2017

TASK NO. F.F.Y.

Amount

PROGRAM INCOMEPAID MEDIA

2016-17

2015-16

4

DI1721

OTS-38a* (Rev. 01/16)

PROJECTED EXPENDITURES

210,000.00$

210,000.00$

-$

-$

-$

-$

-$

-$

STATUTE

2015

2016

-

-

20.616

420,000.00

SCHEDULE A

GRANT DESCRIPTION GRANT NO. DI1721

PAGE 1

OTS-38b (Rev. 4/16)

1. PROBLEM STATEMENT The Los Angeles County Sheriff’s Department (LASD) – Scientific Services Bureau (SSB) is responsible for all ante-mortem criminal forensic toxicology analyses within the County of Los Angeles, exclusive only of Los Angeles City. This includes service to over 100 local, state, and federal law enforcement agencies, including the California Highway Patrol. In calendar year 2013, drug-impaired driving submissions totaled 2,146; in calendar year 2014, drug-impaired driving submissions totaled 2,831; and in calendar year 2015, drug-impaired driving submissions totaled 2,172. LASD-SSB would like to introduce/reintroduce the use of liquid chromatography tandem mass spectrometry (LC/MS/MS) for the confirmatory and quantitative analysis of drug-impaired driving submissions, for the following two reasons: 1) The majority of drug-impaired driving submissions over the past three years were from subjects

suspected of driving while under the influence of marijuana. The traditional method for confirming the presence of marijuana in forensic toxicology samples involves the use of gas chromatography mass spectrometry (GC/MS). This method allows for detection of a non-psychoactive metabolite (carboxy-THC) of the parent drug. However, this metabolite remains in the blood long after the psychoactive parent drug has been fully metabolized. Therefore, the presence of the metabolite in a blood sample only offers indirect support for a driving-under-the-influence charge.

A more effective method for confirming the presence of marijuana in forensic toxicology samples involves the use of LC/MS/MS. This method allows for detection of the psychoactive parent drug (Delta 9-THC), which offers direct support for a driving-under-the-influence charge.

2) LC/MS/MS is generally superior to traditional GC/MS for forensic toxicology applications. It requires

less sample preparation on the part of the analyst, thereby allowing for a higher overall case output with a fixed number of analysts. It also offers increased sensitivity and selectivity, allowing for the detection of analytes that cannot be detected via GC/MS (such as Delta 9-THC).

LASD-SSB has historically used GC/MS. In approximately 2007, an LC/MS/MS instrument was procured and validated for use in marijuana confirmation assays. Beginning in 2013, the LC/MS/MS instrument began to experience technical problems and was intermittently out of service for maintenance and repairs. Mid-year 2015 the LC/MS/MS had to be removed from service indefinitely. That instrument is also nearing the end of its expected service life of ten years. When the LC/MS/MS was removed from service, the GC/MS marijuana confirmation method was reintroduced and is currently the only method available.

SCHEDULE A

GRANT DESCRIPTION GRANT NO. DI1721

PAGE 2

OTS-38b (Rev. 4/16)

LASD-SSB would like to reintroduce the use of LC/MS/MS technology for the confirmation and quantitation of marijuana in drug-impaired driving forensic toxicology samples, as well as expand the use of this technology for the confirmation and quantitation of other drugs. This will aid local law enforcement and prosecutorial agencies in the investigation and prosecution of drug-impaired driving cases, thereby increasing safety on roadways within Los Angeles County. LASD-SSB will follow established LA County Sheriff’s Department detection limits; but resources permitting, is working towards meeting additional detection limits. Additionally, LASD-SSB is in the process of expanding the panel to include kits specific for Oxycodone/Oxymorphone, Carisoprodol/Meprobamate (Soma), and Zolpidem (Ambien). This is coming at substantial financial cost, which will increase by approximately 50% over the current panel. LASD-SSB hopes to have this implemented in 2017, and this will meet the NHTSA recommended cutoffs for these drugs. LASD-SSB intends to partner with the Los Angeles County District Attorney’s Office (LADA) in LADA’s efforts to better equip Deputy District Attorneys (DDAs) to prosecute drug-impaired driving cases. Meetings have already been held with personnel from the LADA Training Division to discuss training plans for DDAs. LASD-SSB has committed to assisting LADA in its training efforts by providing instruction to DDAs on the technical aspects of forensic toxicology. This partnership will assist the LADA in making better use of LASD-SSB analytical results, thereby increasing the efficiency and effectiveness of drug-impaired driving prosecutions. These efforts will ultimately serve to increase traffic safety in Los Angeles County and surrounding areas.

2. PERFORMANCE MEASURES

A. Goals:

1) To efficiently and effectively analyze toxicology submissions in drug-impaired driving cases, thereby aiding the criminal justice system in its dealing with these cases.

2) To effectively analyze toxicology submissions in suspected marijuana drug-impaired driving cases by detecting the psychoactive parent drug, when present.

3) To increase the laboratory capacity to analyze toxicology submissions in drug-impaired driving cases.

4) To decrease toxicology submission turnaround times in drug-impaired driving cases.

5) To assist the Los Angeles County District Attorney’s Office by providing training to Deputy District Attorneys in understanding and applying toxicology results in drug-impaired driving cases.

SCHEDULE A

GRANT DESCRIPTION GRANT NO. DI1721

PAGE 3

OTS-38b (Rev. 4/16)

B. Objectives:

1) To purchase and install an LC/MS/MS instrument.

2) To validate the LC/MS/MS instrument for use in marijuana toxicology confirmation and quantitation

casework within three months of installation.

3) To conduct analyses of suspected marijuana toxicology submissions using LC/MS/MS methods capable of detecting the psychoactive components of marijuana.

4) To develop and validate methods for the confirmation and quantitation of additional drugs via LC/MS/MS.

5) To provide training to stakeholders regarding laboratory toxicological capabilities, including screening and confirmation of submissions.

6) To screen and confirm Tier 1 drugs (except Cocaethylene, Phenobarbital, and 6-Acetylmorphine) in

blood submissions at the suggested detection limits as shown in Table II* or in accordance with established LA County Sheriff’s Department detection limits. Resources permitting, to move towards identifying some or many of the Tier 2 drugs listed in Table V*. (*See attached LASD-SSB document dated December 30, 2016 and “Recommendations for Toxicological Investigation of Drug-Impaired Driving and Motor Vehicle Fatalities” article). This may take 2 – 3 years after the conclusion of the grant.

7) To submit a report to OTS that compares the lab’s analysis capabilities before and after the LC/MS/MS

methods, turn-around times, backlogs, and drugs detected. This may take 2 – 3 years after the conclusion of the grant.

3. METHOD OF PROCEDURE

A. Phase 1 - Program Preparation, Training and Implementation (1st Quarter of Grant Year)

Hire and/or train necessary staff needed for the grant program. Develop and execute purchase with vendors. Purchase grant funded items needed to implement the program.

B. Phase 2 - Program Operations (Throughout Grant Year)

SCHEDULE A

GRANT DESCRIPTION GRANT NO. DI1721

PAGE 4

OTS-38b (Rev. 4/16)

Upon installation of an LC/MS/MS instrument, begin the validation process for marijuana confirmation and quantitation.

Upon completion of the validation of the LC/MS/MS instrument, begin using the instrument in marijuana toxicology casework.

Depending on the marijuana toxicology caseload and instrument availability, begin the process of developing methods for the confirmation and quantitation of other drugs.

C. Phase 3 – Data Collection & Reporting (Throughout Grant Year)

Invoice Claims (due January 30, April 30, July 30, and November 30) Quarterly Performance Reports (due January 30, April 30, July 30, and November 30)

Collect and report quarterly, appropriate data that supports the progress of goals and objectives.

Provide a brief list of activity conducted, procurement of grant-funded items, and significant media activities. Include status of grant-funded personnel, status of contracts, challenges, or special accomplishments.

Provide a brief summary of quarterly accomplishments and explanations for objectives not

completed or plans for upcoming activities.

Collect, analyze, and report statistical data relating to the grant goals and objectives.

4. METHOD OF EVALUATION

Using the data compiled during the grant, the Grant Director will complete the “Final Evaluation” section in the fourth/final Quarterly Performance Report (QPR). The Final Evaluation should provide a brief summary of the grant’s accomplishments, challenges and significant activities. This narrative should also include whether goals and objectives were met, exceeded, or an explanation of why objectives were not completed.

5. ADMINISTRATIVE SUPPORT

This program has full support of the County of Los Angeles. Every effort will be made to continue the activities after the grant conclusion.

SCHEDULE B DETAILED BUDGET ESTIMATE

GRANT NO. DI1721

TOTAL AMOUNT

$420,000.00

CFDA 1/1/17-9/30/17

-$ -$

-$ -$

-$ -$

20.616 12,000.00$ 12,000.00$ 20.616 8,000.00$ 8,000.00$

20,000.00$ 20,000.00$

-$ -$

-$ -$

20.616 400,000.00$ 400,000.00$

400,000.00$ 400,000.00$

-$ -$

-$ -$

-$ -$

-$ -$

420,000.00$ 420,000.00$

Category Sub-Total

Category Sub-Total

None

F. INDIRECT COSTSNone

E. OTHER DIRECT COSTS

GRANT TOTAL

D. EQUIPMENT

Category Sub-Total

COST CATEGORY

None

NoneC. CONTRACTUAL SERVICES

Category Sub-Total

FUND NUMBER

405d AL

CATALOG NUMBER (CFDA)

20.616

FUND DESCRIPTION

National Priority Safety Programs

A. PERSONNEL COSTS

Positions and Salaries

TOTAL COST TO GRANT

Liquid Chromatograph Tandem Mass Spectrometer

Full-Time

FISCAL YEAR ESTIMATES

In-StateOut-of-State

Category Sub-Total

Category Sub-Total

B. TRAVEL EXPENSE

OvertimeNone

OTS-38d (Rev. 4/16) Page 1 of 1

SCHEDULE B-1

GRANT NO. DI1721

BUDGET NARRATIVE Page 1

OTS-38f (Rev. 4/16)

PERSONNEL COSTS

None

TRAVEL EXPENSE

In State Costs are included for appropriate staff to attend conferences and training events supporting the grant goals and objectives and/or traffic safety. Local mileage for grant activities and meetings is included. Anticipated travel may include the California Association of Toxicologist meeting. All conferences, seminars, meetings or training not specifically identified in the Schedule B-1 (Budget Narrative) must be approved by OTS. All travel claimed must be at the agency approved rate. Per Diem may not be claimed for meals provided at conferences when registration fees are paid with OTS grant funds. Out-Of-State Appropriate staff may attend the Society of Forensic Toxicologist annual meeting in support of the grant goals and objectives. All out-of-state travel not specifically identified in the Schedule B-1 (Budget Narrative) must receive written approval from OTS. All travel claimed must be at the agency approved rate. Per Diem may not be claimed for meals provided at conferences when registration fees are paid with OTS grant funds.

CONTRACTUAL SERVICES

None

EQUIPMENT

Liquid Chromatograph Tandem Mass Spectrometer (LCMSMS): Complete LCMSMS system to include: liquid chromatograph with multi-sampler and other required components; triple quadrupole mass spectrometer; nitrogen generator; workstation PC, instrument-specific software & licenses, and printer; installation and setup; chemical analysis application consulting & training.

OTHER DIRECT COSTS

None

INDIRECT COSTS

None

PROGRAM INCOME

There will be no program income generated from this grant.

EXHIBIT A

CERTIFICATIONS AND ASSURANCES

Certifications and Assurances (Rev. 5/16)

Page 1

Failure to comply with applicable Federal statutes, regulations, and directives may subject Grantee Agency officials to civil or criminal penalties and/or place the State in a high risk grantee status in accordance with 49 CFR §18.12.

The officials named on the grant agreement, certify by way of signature on the grant agreement signature page, that the Grantee Agency complies with all applicable Federal statutes, regulations, and directives and State rules, guidelines, policies and laws in effect with respect to the periods for which it receives grant funding. Applicable provisions include, but are not limited to, the following:

• 23 U.S.C. Chapter 4—Highway Safety Act of 1966, as amended

• 49 CFR Part 18—Uniform Administrative Requirements for Grants and Cooperative Agreements to

State and Local Governments

• 23 CFR Part 1200—Uniform Procedures for State Highway Safety Grant Programs

NONDISCRIMINATION The Grantee Agency will comply with all Federal statutes and implementing regulations relating to nondiscrimination. These include but are not limited to: (a) Title VI of the Civil Rights Act of 1964 (Pub. L. 88- 352), which prohibits discrimination on the basis of race, color or national origin (and 49 CFR Part 21); (b) Title IX of the Education Amendments of 1972, as amended (20 U.S.C. 1681-1683 and 1685-1686), which prohibits discrimination on the basis of sex; (c) Section 504 of the Rehabilitation Act of 1973, as amended (29 U.S.C. 794), and the Americans with Disabilities Act of 1990 (Pub. L. 101-336), as amended (42 U.S.C. 12101, et seq.), which prohibits discrimination on the basis of disabilities (and 49 CFR Part 27); (d) the Age Discrimination Act of 1975, as amended (42 U.S.C. 6101-6107), which prohibits discrimination on the basis of age; (e) the Civil Rights Restoration Act of 1987 (Pub. L. 100-259), which requires Federal-aid recipients and all sub-recipients to prevent discrimination and ensure nondiscrimination in all of their programs and activities; (f) the Drug Abuse Office and Treatment Act of 1972 (Pub. L. 92-255), as amended, relating to nondiscrimination on the basis of drug abuse; (g) the comprehensive Alcohol Abuse and Alcoholism Prevention, Treatment and Rehabilitation Act of 1970 (Pub. L. 91-616), as amended, relating to nondiscrimination on the basis of alcohol abuse or alcoholism; (h) Sections 523 and 527 of the Public Health Service Act of 1912, as amended (42 U.S.C. 290dd-3 and 290ee-3), relating to confidentiality of alcohol and drug abuse patient records; (i) Title VIII of the Civil Rights Act of 1968, as amended (42 U.S.C. 3601, et seq.), relating to nondiscrimination in the sale, rental or financing of housing; (j) any other nondiscrimination provisions in the specific statute(s) under which application for Federal assistance is being made; and (k) the requirements of any other nondiscrimination statute(s) which may apply to the application.

EXHIBIT A

CERTIFICATIONS AND ASSURANCES

Certifications and Assurances (Rev. 5/16)

BUY AMERICA ACT

Page 2

The Grantee Agency will comply with the provisions of the Buy America Act (49 U.S.C. 5323(j)), which contains the following requirements:

Only steel, iron and manufactured products produced in the United States may be purchased with Federal funds unless the Secretary of Transportation determines that such domestic purchases would be inconsistent with the public interest, that such materials are not reasonably available and of a satisfactory quality, or that inclusion of domestic materials will increase the cost of the overall project contract by more than 25 percent. Clear justification for the purchase of non-domestic items must be in the form of a waiver request submitted to and approved by the Secretary of Transportation.

POLITICAL ACTIVITY (HATCH ACT) The Grantee Agency will comply with provisions of the Hatch Act (5 U.S.C. 1501-1508) which limits the political activities of employees whose principal employment activities are funded in whole or in part with Federal funds.

CERTIFICATION REGARDING FEDERAL LOBBYING Certification for Contracts, Grants, Loans, and Cooperative Agreements

The undersigned certifies, to the best of his or her knowledge and belief, that:

1. No Federal appropriated funds have been paid or will be paid, by or on behalf of the undersigned, to any

person for influencing or attempting to influence an officer or employee of any agency, a Member of Congress, an officer or employee of Congress, or an employee of a Member of Congress in connection with the awarding of any Federal contract, the making of any Federal grant, the making of any Federal loan, the entering into of any cooperative agreement, and the extension, continuation, renewal, amendment, or modification of any Federal contract, grant, loan, or cooperative agreement.

2. If any funds other than Federal appropriated funds have been paid or will be paid to any person for

influencing or attempting to influence an officer or employee of any agency, a Member of Congress, an officer or employee of Congress, or an employee of a Member of Congress in connection with this Federal contract, grant, loan, or cooperative agreement, the undersigned shall complete and submit Standard Form- LLL, “Disclosure Form to Report Lobbying,” in accordance with its instructions.

3. The undersigned shall require that the language of this certification be included in the award documents for

all sub-award at all tiers (including subcontracts, sub-grants, and contracts under grant, loans, and cooperative agreements) and that all sub-recipients shall certify and disclose accordingly.

This certification is a material representation of fact upon which reliance was placed when this transaction was made or entered into. Submission of this certification is a prerequisite for making or entering into this transaction imposed by section 1352, title 31, U.S. Code. Any person who fails to file the required certification shall be subject to a civil penalty of not less than $10,000 and not more than $100,000 for each such failure.

EXHIBIT A

CERTIFICATIONS AND ASSURANCES

Certifications and Assurances (Rev. 5/16)

RESTRICTION ON STATE LOBBYING

Page 3

None of the funds under this program will be used for any activity specifically designed to urge or influence a State or local legislator to favor or oppose the adoption of any specific legislative proposal pending before any State or local legislative body. Such activities include both direct and indirect (e.g., “grassroots”) lobbying activities, with one exception. This does not preclude a State official whose salary is supported with NHTSA funds from engaging in direct communications with State or local legislative officials, in accordance with customary State practice, even if such communications urge legislative officials to favor or oppose the adoption of a specific pending legislative proposal.

CERTIFICATION REGARDING DEBARMENT AND SUSPENSION Instructions for Primary Certification

1. By signing and submitting this grant agreement, the Grantee Agency Official is providing the certification

set out below. 2. The inability of a person to provide the certification required below will not necessarily result in denial of

participation in this covered transaction. The prospective participant shall submit an explanation of why it cannot provide the certification set out below. The certification or explanation will be considered in connection with the department or agency's determination whether to enter into this transaction. However, failure of the Grantee Agency Official to furnish a certification or an explanation shall disqualify such person from participation in this transaction.

3. The certification in this clause is a material representation of fact upon which reliance was placed when the

department or agency determined to enter into this transaction. If it is later determined that the Grantee Agency Official knowingly rendered an erroneous certification, in addition to other remedies available to the Federal Government, the department or agency may terminate this transaction for cause or default.

4. The Grant Agency Official shall provide immediate written notice to the department or agency to which this

grant agreement is submitted if at any time the Grantee Agency Official learns its certification was erroneous when submitted or has become erroneous by reason of changed circumstances.

5. The terms covered transaction, debarred, suspended, ineligible, lower tier covered transaction, participant,

person, primary covered transaction, principal, grant agreement, and voluntarily excluded, as used in this clause, have the meaning set out in the Definitions and coverage sections of 49 CFR Part 29. You may contact the department or agency to which this grant agreement is being submitted for assistance in obtaining a copy of those regulations.

6. The Grantee Agency Official agrees by submitting this grant agreement that, should the proposed covered

transaction be entered into, it shall not knowingly enter into any lower tier covered transaction with a person who is proposed for debarment under 48 CFR Part 9, subpart 9.4, debarred, suspended, declared ineligible, or voluntarily excluded from participation in this covered transaction, unless authorized by the department or agency entering into this transaction.

EXHIBIT A

CERTIFICATIONS AND ASSURANCES

Certifications and Assurances (Rev. 5/16)

Page 47. The Grantee Agency Official further agrees by submitting this grant agreement that it will include the clause

titled “Certification Regarding Debarment, Suspension, Ineligibility and Voluntary Exclusion-Lower Tier Covered Transaction,” provided by the department or agency entering into this covered transaction, without modification, in all lower tier covered transactions and in all solicitations for lower tier covered transactions.

8. A participant in a covered transaction may rely upon a certification of a prospective participant in a lower

tier covered transaction that it is not proposed for debarment under 48 CFR Part 9, subpart 9.4, debarred, suspended, ineligible, or voluntarily excluded from the covered transaction, unless it knows that the certification is erroneous. A participant may decide the method and frequency by which it determines the eligibility of its principals. Each participant may, but is not required to, check the list of Parties Excluded from Federal Procurement and Non-procurement Programs.

9. Nothing contained in the foregoing shall be construed to require establishment of a system of records in

order to render in good faith the certification required by this clause. The knowledge and information of a participant is not required to exceed that which is normally possessed by a prudent person in the ordinary course of business dealings.

10. Except for transactions authorized under paragraph 6 of these instructions, if a participant in a covered

transaction knowingly enters into a lower tier covered transaction with a person who is proposed for debarment under 48 CFR Part 9, subpart 9.4, suspended, debarred, ineligible, or voluntarily excluded from participation in this transaction, in addition to other remedies available to the Federal Government, the department or agency may terminate this transaction for cause or default.

Certification Regarding Debarment, Suspension, and Other Responsibility Matters-Primary Covered Transactions (1) The Grantee Agency Official certifies to the best of its knowledge and belief, that its principals:

(a) Are not presently debarred, suspended, proposed for debarment, declared ineligible, or voluntarily excluded by any Federal department or agency;

(b) Have not within a three-year period preceding this grant agreement been convicted of or had a civil judgment rendered against them for commission of fraud or a criminal offense in connection with obtaining, attempting to obtain, or performing a public (Federal, State or local) transaction or contract under a public transaction; violation of Federal or State antitrust statutes or commission of embezzlement, theft, forgery, bribery, falsification or destruction of record, making false statements, or receiving stolen property;

(c) Are not presently indicted for or otherwise criminally or civilly charged by a governmental entity (Federal, State or Local) with commission of any of the offenses enumerated in paragraph (1)(b) of this certification; and

(d) Have not within a three-year period preceding this application/grant agreement had one or more public transactions (Federal, State, or local) terminated for cause or default.

(2) Where the Grantee Agency Official is unable to certify to any of the Statements in this certification, such prospective participant shall attach an explanation to this grant agreement.

EXHIBIT A

CERTIFICATIONS AND ASSURANCES

Certifications and Assurances (Rev. 5/16)

Page 5 Instructions for Lower Tier Certification 1. By signing and submitting this grant agreement, the prospective lower tier participant is providing the

certification set out below. 2. The certification in this clause is a material representation of fact upon which reliance was placed when this

transaction was entered into. If it is later determined that the prospective lower tier participant knowingly rendered an erroneous certification, in addition to other remedies available to the Federal government, the department or agency with which this transaction originated may pursue available remedies, including suspension and/or debarment.

3. The prospective lower tier participant shall provide immediate written notice to the person to which this grant agreement is submitted if at any time the prospective lower tier participant learns that its certification was erroneous when submitted or has become erroneous by reason of changed circumstances.

4. The terms covered transaction, debarred, suspended, ineligible, lower tier covered transaction, participant,

person, primary covered transaction, principal, grant agreement, and voluntarily excluded, as used in this clause, have the meanings set out in the Definition and Coverage sections of 49 CFR Part 29. You may contact the person to whom this grant agreement is submitted for assistance in obtaining a copy of those regulations.

5. The prospective lower tier participant agrees by submitting this grant agreement that, should the proposed

covered transaction be entered into, it shall not knowingly enter into any lower tier covered transaction with a person who is proposed for debarment under 48 CFR Part 9, subpart 9.4, debarred, suspended, declared ineligible, or voluntarily excluded from participation in this covered transaction, unless authorized by the department or agency with which this transaction originated.

6. The prospective lower tier participant further agrees by submitting this grant agreement that it will include

the clause titled “Certification Regarding Debarment, Suspension, Ineligibility and Voluntary Exclusion— Lower Tier Covered Transaction,” without modification, in all lower tier covered transactions and in all solicitations for lower tier covered transactions. (See below)

7. A participant in a covered transaction may rely upon a certification of a prospective participant in a lower

tier covered transaction that it is not proposed for debarment under 48 CFR Part 9, subpart 9.4, debarred, suspended, ineligible, or voluntarily excluded from the covered transaction, unless it knows that the certification is erroneous. A participant may decide the method and frequency by which it determines the eligibility of its principals. Each participant may, but is not required to, check the List of Parties Excluded from Federal Procurement and Non-procurement Programs.

8. Nothing contained in the foregoing shall be construed to require establishment of a system of records in

order to render in good faith the certification required by this clause. The knowledge and information of a participant is not required to exceed that which is normally possessed by a prudent person in the ordinary course of business dealings.

EXHIBIT A

CERTIFICATIONS AND ASSURANCES

Certifications and Assurances (Rev. 5/16)

Page 6 9. Except for transactions authorized under paragraph 5 of these instructions, if a participant in a covered

transaction knowingly enters into a lower tier covered transaction with a person who is proposed for debarment under 48 CFR Part 9, subpart 9.4, suspended, debarred, ineligible, or voluntarily excluded from participation in this transaction, in addition to other remedies available to the Federal government, the department or agency with which this transaction originated may pursue available remedies, including suspension and/or debarment.

Certification Regarding Debarment, Suspension, Ineligibility and Voluntary Exclusion—Lower Tier Covered Transactions:

1. The prospective lower tier participant certifies, by submission of this grant agreement, that neither it nor its

principals is presently debarred, suspended, proposed for debarment, declared ineligible, or voluntarily excluded from participation in this transaction by any Federal department or agency.

2. Where the prospective lower tier participant is unable to certify to any of the statements in this certification,

such prospective participant shall attach an explanation to this grant agreement.

Los Angeles County Sheriff’s Department

Scientific Services Bureau

Toxicology Detection Limits and Cutoffs

December 30, 2016

The Los Angeles County Sheriff’s Department, Scientific Services Bureau, Toxicology Section

conducts screening and confirmation tests of blood submissions for the presence of drugs.

The following is the blood screening panel currently in use:

Drug Category Testing Kit Calibrator Cutoff

Barbiturates Immunalysis 210 Secobarbital 200 ng/ml

Cocaine Immunalysis 212 Benzoylecgonine 50 ng/ml

Benzodiazepines Immunalysis 214 Nordiazepam 50 ng/ml

Amphetamines Immunalysis 211 Methamphetamine 20 ng/ml

Opiates Immunalysis 207 Morphine 20 ng/ml

PCP Immunalysis 208 PCP 5 ng/ml

Cannabinoids Immunalysis 205 Carboxy-THC 5 ng/ml

Each of the listed screening kits has cross-reactivity with many drugs in its class. On the

following page is a matrix that lists Tier 1 drugs1 and their estimated cutoffs, based on the

calibrator listed above and the cross-reactivity determined by the manufacturer based on

general inhibition curves. For some assays, as indicated in the matrix, the calibrator and cutoff

in use are different from that used by the manufacturer to determine cross-reactivity

percentages. Therefore, for these assays, the estimated cutoffs for drugs other than the

calibrator may not be accurate. Empirical testing will be required to accurately determine

these cutoffs.

LASD/SSB - Toxicology Detection Limits and Cutoffs – Dec. 30, 2016

Kit Drug % Cross-Reactivity Estimated Cutoff

Barbiturates Secobarbital N/A - Calibrator 200 ng/ml Butalbital 50% 400 ng/ml Phenobarbital 14.3% 1400 ng/ml Note: Cross-reactivity percentages based on Secobarbital at 10 ng/ml.

Cocaine Benzoylecgonine N/A - Calibrator 50 ng/ml Cocaine 66% 76 ng/ml

Benzodiazepines Nordiazepam N/A - Calibrator 50 ng/ml Lorazepam 180% 28 ng/ml Oxazepam 200% 25 ng/ml Clonaepam 140% 36 ng/ml 7-Aminoclonazepam 80% 62 ng/ml Alprazolam 360% 14 ng/ml OH-Alprazolam 140% 35 ng/ml Diazepam 140% 35 ng/ml Temazepam 400% 13 ng/ml Note: Cross-reactivity percentages based on Oxazepam at 250 pg/ml. Amphetamines Methamphetamine N/A - Calibrator 20 ng/ml d-Amphetamine 2% 1000 ng/ml MDMA 135% 15 ng/ml Note: Cross-reactivity percentages based on d-Methamphetamine at 50 ng/ml. Opiates Morphine N/A - Calibrator 20 ng/ml 6-Acetylmorphone 83% 24 ng/ml Codeine 200% 10 ng/ml Hydrocodone 93% 22 ng/ml Hydromorphone 81% 25 ng/ml Oxycodone 21% 95 ng/ml Oxymorphone 20% 100 ng/ml Note: Cross-reactivity percentages based on Morphine at 25 ng/ml. PCP PCP N/A - Calibrator 5 ng/ml

Cannabinoids Carboxy THC N/A - Calibrator 5 ng/ml

LASD/SSB - Toxicology Detection Limits and Cutoffs – Dec. 30, 2016

A validation is under way to add kits specific for Carisoprodol/Meprobamate (Immunalysis 231),

Zolpidem (Immunalysis 233), and Oxycodone/Oxymorphone (Immunalysis 221B) to the

screening panel.

At the present time, all Tier 1 drugs are confirmed at or below the listed cutoffs in Table II2,

with the following exceptions:

- Phenobarbital, which is confirmed at or below 1000ng/ml,

- THC and 11-OH-THC, which are not confirmed at the present time due to the LC/MS/MS

instrument being out of service, and

- Cocaethylene and 6-Acetylmorphone, which are not confirmed.

1 Logan, B., et al. “Recommendations for Toxicological Investigation of Drug-Impaired Driving and Motor Vehicle Fatalities.” Journal of Analytical Toxicology, Vol. 37, No. 8 (2013): 552-558. 2 Ibid, 555.